open access

Vol 71, No 2 (2021)
Invited editorial
Published online: 2021-04-06
Get Citation

Well-differentiated neuroendocrine neoplasms (NENs) of the digestive system – a diagnostic and therapeutic problem

Daria Handkiewicz-Junak, Agnieszka Czarniecka
DOI: 10.5603/NJO.2021.0023
·
Nowotwory. Journal of Oncology 2021;71(2):115-116.

open access

Vol 71, No 2 (2021)
Invited editorial
Published online: 2021-04-06

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Well-differentiated neuroendocrine neoplasms (NENs) of the digestive system – a diagnostic and therapeutic problem

Journal

Nowotwory. Journal of Oncology

Issue

Vol 71, No 2 (2021)

Article type

Invited editorial

Pages

115-116

Published online

2021-04-06

DOI

10.5603/NJO.2021.0023

Bibliographic record

Nowotwory. Journal of Oncology 2021;71(2):115-116.

Authors

Daria Handkiewicz-Junak
Agnieszka Czarniecka

References (10)
  1. Baldys-Waligorska A, Nowak W. Neuroendocrine neoplasms of the digestive system-current classification and terminology. Nowotwory Journal of Oncology. 2021; 71(1): 26–37.
  2. Manguso N, Gangi A, Nissen N, et al. Long-Term Outcomes after Elective Emergency Surgery for Small Bowel Neuroendocrine Tumors. Am Surg. 2018; 84(10): 1570–1574.
  3. Sundin A, Arnold R, Baudin E, et al. Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. Neuroendocrinology. 2017; 105(3): 212–244.
  4. Knigge U, Capdevila J, Bartsch DK, et al. Antibes Consensus Conference Participants, Antibes Consensus Conference participants. ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation. Neuroendocrinology. 2017; 105(3): 310–319.
  5. Caplin ME, Pavel M, Ćwikła JB, et al. CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014; 371(3): 224–233.
  6. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26(13): 2124–2130.
  7. Eriksson J, Garmo H, Hellman P, et al. The Influence of Preoperative Symptoms on the Death of Patients with Small Intestinal Neuroendocrine Tumors. Ann Surg Oncol. 2017; 24(5): 1214–1220.
  8. Yao JC, Fazio N, Singh S, et al. RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016; 387(10022): 968–977.
  9. Chan DL, Segelov E, Singh S. Everolimus in the management of metastatic neuroendocrine tumours. Therap Adv Gastroenterol. 2017; 10(1): 132–141.
  10. Strosberg J, El-Haddad G, Wolin E, et al. NETTER-1 Trial Investigators. Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017; 376(2): 125–135.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl